- Home
- PG vs AZN Comparison
PG vs AZN Comparison
Compare PG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PG | AZN |
|---|---|---|
| Founded | 1837 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.3B | 316.4B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PG | AZN |
|---|---|---|
| Price | $151.02 | $174.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $163.64 | N/A |
| AVG Volume (30 Days) | ★ 7.0M | 1.9M |
| Earning Date | 04-24-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.89% | 1.73% |
| EPS Growth | ★ 8.14 | N/A |
| EPS | ★ 5.36 | N/A |
| Revenue | ★ $84,284,000,000.00 | N/A |
| Revenue This Year | $5.76 | $10.34 |
| Revenue Next Year | $2.57 | $6.43 |
| P/E Ratio | ★ $28.20 | $31.91 |
| Revenue Growth | ★ 0.29 | N/A |
| 52 Week Low | $137.62 | $68.62 |
| 52 Week High | $166.90 | $212.71 |
Technical Indicators
Market Signals| Indicator | PG | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 59.89 | 38.81 |
| Support Level | $139.96 | $174.60 |
| Resistance Level | $152.77 | $209.98 |
| Average True Range (ATR) | 2.85 | 3.23 |
| MACD | 0.77 | -0.37 |
| Stochastic Oscillator | 81.36 | 9.19 |
Price Performance
Historical ComparisonAbout PG Procter & Gamble Company (The)
Since its founding in 1837, Procter & Gamble has become one of the world's largest consumer product manufacturers, with annual sales of nearly $85 billion. It operates with a lineup of leading brands, including more than 20 that generate annual global sales of more than $1 billion each, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent just more than half of the firm's consolidated total.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.